Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766699 | 1.00 | AR (0.76) | AR | |
| SCHEMBL26799887 | 1.00 | AR (0.76) | AR | |
| SCHEMBL13610153 | 0.92 | AR (0.73) | AR | |
| SCHEMBL12591156 | 0.91 | AR (0.65) | AR | |
| SCHEMBL2769146 | 0.91 | AR (0.65) | AR | |
| SCHEMBL5685876 | 0.91 | AR (0.69) | AR | |
| SCHEMBL2766751 | 0.91 | AR (0.63) | AR | |
| SCHEMBL2767799 | 0.91 | AR (0.69) | AR | |
| SCHEMBL5685907 | 0.91 | AR (0.63) | AR | |
| SCHEMBL2767389 | 0.90 | AR (0.64) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744149-B2 | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) | GTX, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170209407-A1 | METHOD OF TREATING HER2-POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2017-07-27 | — | — | US | disclosed |
| US-20160128968-A1 | METHOD OF TREATING ANDROGEN RECEPTOR (AR) -POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS) | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2016-05-12 | — | — | US | disclosed |
| US-7919647-B2 | N-(3-substituted-4-cyano)phenyl-2-hydroxy-2-methyl-3-(4-cyano)phenoxy propamides; spermatogenesis inhibitors, hormone replacement therapy, anticarcinogenic, antiproliferative agents for prostate cancer, apoptotic agents; bone and muscle disorders | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1641745-B1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | ORION CORP (FI) | 2010-04-14 | — | — | EP | disclosed |
| US-7390923-B2 | Propionamide derivatives useful as androgen receptor modulators | ORION CORPORATION (FI) | 2008-06-24 | — | — | US | disclosed |
| US-20070123512-A1 | Propionamide derivatives useful as androgen receptor modulators | ORION CORPORATION (FI) | 2007-05-31 | — | — | US | disclosed |
| US-7205437-B2 | Selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205437-B2 | Selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1641745-A1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | Orion Corporation (FI) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000794-A1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | ORION CORPORATION (FI) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123512-A1 | Propionamide derivatives useful as androgen receptor modulators | NR5A1, FSHR, GNRHR | AR 4/4885 |
| US-20160128968-A1 | METHOD OF TREATING ANDROGEN RECEPTOR (AR) -POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS) | AR, CYP19A1, ERBB2 | AR 1/4885 |
| US-20170209407-A1 | METHOD OF TREATING HER2-POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, PGR, CYP19A1 | AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.